quantification of specific IgE & IgG against pigeon allergens in the blood serum of asthmatic patients. Methods: A total of 200 asthmatic patients diagnosed as per GINA guideline (15-58 years old) were enrolled for the study. All subjects underwent routine investigations and skin prick testing against common aero-allergens and pigeon allergens. All patients underwent serum estimation of specific IgE and IgG against pigeon droppings and feathers with the help of ImmunoCAP100. Results: Out of the total 200 subjects (81 males and 119 females) history of exposure to pigeons was present in 108 patients (54%). Out of the 200 patients, 68 (34%) had positive SPT to ≤ 3 common aeroallergens and 40 (20%) SPT positive ≥ 3 common aeroallergens. In SPT positivity of pigeon allergens feathers and droppings, 4 patients (2%) and 14 (7%) patients were positive respectively. The mean value of specific IgE & IgG of SPT against droppings was 1.4 KUA/L and 28.12 MgA/L and feathers were 0.0075 KUA/L and 9.625 MgA/L respectively. Specific IgE of pigeon exposure against droppings and feather was higher in patients exposed to pigeon droppings and feathers with their mean values 0.31KUA/L (p = 0.013) and 0.093 KUA/L (p = 0.001) in comparison to non-exposed groups with their mean values droppings 0.15 KUA/L and feathers 0.041 KUA/L. Specific IgG of patients exposed group against droppings and feather was higher 25.52 MgA/L (p = 0.009) and 5.61 MgA/L (p = 0.064) in comparison to nonexposed groups dropping and feather 20.61MgA/L and 4.60 MgA/L respectively. Conclusions: Specific IgE and IgG against pigeon droppings and feathers exposed patients was high in comparison to non-exposed asthmatic patients. Background: Allergic rhinitis (AR) is currently recognized as a T helper cell type 2 (Th2) driven disease with typically increased levels of relevant cytokines, such as interleukin (IL)-4 and IL-13 found locally in nasal tissues. The aim of the current study was to determine if nasal allergen challenge (NAC) could affect IL-4 and IL-13 protein and gene expression in birch-stimulated peripheral blood mononuclear cells (PBMCs) cultures.
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Methods:
Consenting individuals (4 birch-allergic and 5 non-allergic) were administered increasing concentrations of birch pollen extract intranasally until each participant achieved qualifying criteria for a positive NAC [Total Nasal Symptom Score (TNSS) ≥ 8 and % Peak Nasal Inspiratory Flow (PNIF) fall ≥ 50%]. At baseline and 4 h post-NAC, peripheral blood samples were collected, PBMCs isolated, and stimulated for 5 days with birch pollen extract or extract diluent. Cytokines were measured using the Bio-Plex ® 200 system and mRNA expression was assessed through qPCR. Statistical analysis was performed using GraphPad Prism 7.0. Results: Baseline PBMCs post-NAC expressed significantly decreased IL-4 levels (p = 0.0313) and birch-stimulated PBMCs post-NAC demonstrated a decreasing trend for IL-4 levels (p = 0.0742) compared to pre-NAC. No significant difference was observed for PBMC derived IL-13 levels before and after the NAC. There was no significant difference between allergic and non-allergic PBMCs. Trends were observed for increased IL-4 mRNA expression in allergic PBMCs compared to nonallergic PBMCs pre-NAC (p = 0.1111), increased IL-13 mRNA expression in non-allergic birch stimulated PBMCs post-NAC compared to pre-NAC (p = 0.0625), and decreased IL-13 levels post-NAC from nonallergic PBMCs in the diluent condition (p = 0.0625). Conclusions: An expected increase of IL-4 and IL-13 protein and mRNA expression in allergic participants was not observed. This unpredicted result may be a consequence of a low sample size or cellular fatigue after repeated exposure to birch pollen extract. Background: Allergic rhinitis (AR) is a common disorder affecting 20-25% of Canadians. Intranasal corticosteroids (INCS) are a mainstay of AR treatment, and some are available over-the-counter (OTC). The aim of this review was to evaluate the efficacy and safety of intranasal corticosteroids approved for OTC use. Methods: A search using keywords allergic rhinitis, anti-allergic agents, intranasal administration, fluticasone, and triamcinolone was conducted on Ovid MEDLINE and Google Scholar. The search was limited to placebo-controlled studies published from 1991 to present. Studies were included which evaluated the efficacy of intranasal fluticasone propionate or triamcinolone acetonide, for the treatment of seasonal or perennial allergic rhinitis. Results: Six trials met the inclusion criteria, three evaluating fluticasone propionate intranasal spray (FPNS), and three evaluating triamcinolone acetonide intranasal spray (TANS), versus placebo. A total of 1218 and 747 subjects were enrolled in FPNS and TANS trials, respectively. The primary efficacy measure was reduction in nasal symptom scores (NS) . FPNS demonstrated statistically significant reduction in nasal symptoms when compared to placebo (p < 0.01) and reduction in obstruction upon awakening (p < 0.01), indicating efficacy lasting 24 h. One study evaluating reduction in ocular symptoms (OS) showed FPNS significantly reduced OS when compared with placebo (p = 0.002). TANS also demonstrated significant reduction in NS when compared to placebo (p < 0.05) across all trials. Overall, safety evaluations indicated both FPNS and TANS were well tolerated. Background: We reported two potential biomarkers for asthma severity, namely circulating CD4 + CRTh2 + T-cells and CD14 ++ CD16 + PAR2
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+ . Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) is a receptor for PGD2 and expressed by T cells, eosinophils, basophils and type 2 innate lymphoid cells (ILC2). Protease-Activated Receptor-2 (PAR-2) is a pro-inflammatory receptor activated by serine proteases and expressed on many cells, including monocytes and lung resident cells. Our next step to validate the utility of flowcytometric measures as biomarkers for asthma severity was to assess the stability of these markers in asthmatics over time.
Methods: Stability of "% of CD4
+ CRTh2 + T cells" and "% of CD14
++ CD16 + PAR-2 + monocytes" in peripheral blood was studied in asthmatics (n = 19) by flowcytometry. FEV 1 and asthma control questionnaire based on 7 (ACQ7) and 5-point scale (ACQ5) as physiological variables were collected. The stability of total numbers of ILC2 and eosinophils were analysed. Within person stability of laboratory values over 4 visits were calculated using the intraclass correlation (ICC) by R version 3.4.0. Results: The mean age of asthmatics in our study was 45 years. The stability of % of CD4
+

CRTh2
+ T-cells (ICC = 0.20) and % of CD14 ++ CD16 + PAR-2 + (ICC = 0.24) was poor over four visits. Analysis of ICC suggested high stability over the four repeated values in FEV 1 (ICC = 0.90), ACQ5 (ICC = 0.68) and ACQ7 (ICC = 0.75). ICCs were moderate for % of eosinophils (ICC = 0.44) and ILC2 (ICC = 0.45). No correlations were observed between immune cell profiles, FEV 1 , ACQ5 and ACQ7.
Conclusions: % CD4
+
CRTh2
+ T-cells and % CD14 ++ CD16 + PAR-2 + cells varied substantially over the four visits in this asthmatic population. Variability did not correlate with physiological measures of asthma or questionnaire measures of asthma control. The reason for this variability is not known. This study also showed good stability of FEV 1 , ACQ5 and ACQ7 and moderate stability of % of ILC2 and % of eosinophils. Background: In Canada, it is estimated that asthma affects 8.5% of the total population. It is the leading cause of hospital admissions, the third leading cause of work loss, and results in 146,000 emergency room visits annually in the overall population. Omalizumab is indicated for the treatment of adults and adolescents with moderate to severe persistent allergic asthma whose symptoms are inadequately controlled despite optimized standard therapy. Real world effectiveness data assessing the HCU in the Canadian context is limited.
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Objective: This study was a retrospective, pre-post cohort, observational study. The primary objective was to evaluate the health care utilization (HCU) following Omalizumab initiation as assessed by the reduction in number of hospitalizations, emergency room (ER) visits, and oral corticosteroid (OCS) use in patients covered in Ontario. The number of night awakenings was an exploratory endpoint. Results: 148 patients (mean age 57.6; female 62.2%) formed the study population. Omalizumab was associated with a 74.4% reduction in the number of hospitalization (pre vs post-Omalizumab's 12 month treatment period: 0.7 vs 0.2 p < 0.001). 89.9% of patients did not have any asthma related hospitalization. There was a reduction of 87.5% in ER visits (7.3 vs. 0.9 p < 0.001), 66.2% of patients did not have any emergency visit. A 74.7% reduction of the number of high dose OCS by (4.23 vs. 1.07 p < 0.001), 52.7% of patients did not need to take any courses of high dose OCS. The mean number of night awakenings/per week decreased from 6.1 (8.03) to 1.3 (2.79) following 12 month treatment with Omalizumab. Conclusions: There was an observed reduction in the number of hospitalizations, ER visits, and high-dose OCS courses post-Omalizumab use in patients with severe uncontrolled asthma in a real-world setting. The results are consistent with outcomes observed in previous large real-world trials such as the experience registry. Background: The Environmental Exposure Unit (EEU) and Nasal Allergen Challenge (NAC) are both experimental models of Allergic rhinitis (AR). They mimic the inflammatory processes and symptom manifestations associated with exposure to sensitized aeroallergens. Previous studies demonstrated a unique Total Nasal Symptom Score (TNSS) profile following allergen challenge in each model. As AR individuals also experience ocular symptoms, we sought to compare the Total Ocular Symptom Score (TOSS) profiles following allergen challenge in both the EEU and NAC models. Methods: 7 birch-allergic and 4 non-allergic individuals who participated in both an EEU study and a NAC study using birch pollen were included in the analysis. For both studies, TNSS, TOSS, and Total Rhinoconjunctivitis Symptom Scores (TRSS) were collected at baseline, 15 min (NAC only), 30 min, and hourly until 12 h post-challenge (every half hour during first 4 h for EEU). Data was analyzed using GraphPad Prism. Adjustments for multiplicity testing were not made. Results: Peak increases in TOSS were observed at 3 h and 30 min post-challenge in the EEU and NAC respectively. However, they were only significant in the EEU (p < 0.05). In contrast, TRSS peaked at 3 h (p < 0.05) and 15 min (p < 0.05) post-challenge in the EEU and NAC respectively. Overall, a significantly higher mean TRSS (p < 0.05), but not TOSS (p = 0.16), was observed in the EEU compared to the NAC. When comparing TOSS profiles from both models by time point, significant differences were observed at 30 min, 1, 3, 4, 5, 7, and 9 h (all p < 0.05). Conversely, significant differences in TRSS profiles were observed at 30 min, 1 through 9 and 12 h (all p < 0.05) following allergen challenge. Conclusions: Significant ocular symptoms in the EEU may be attributable to the prolonged pollen exposure period and contact with airborne pollen. Significant differences in TRSS within and between each model were primarily driven by differences in TNSS, not TOSS.
A27
Background:
The 'atopic March' describes the progression from atopic dermatitis during infancy to asthma and allergic rhinitis in later childhood. In a Canadian birth cohort, we investigated whether concomitant allergic sensitization enhances subsequent development of these allergic diseases at age 3 years. Methods: At age 1, children completed skin prick testing. Children were considered sensitized if they produced a wheal 2 mm or greater than the negative control to any of ten inhalant or food allergens. Children were also assessed for atopic dermatitis using the diagnostic criteria of the UK Working Party. At age 3, children were assessed for asthma, allergic rhinitis, food allergy, and atopic dermatitis. Data from 2311 children were available. Results: Atopic dermatitis without allergic sensitization was not associated with an increased risk of asthma at age 3, after adjusting for common confounders (RR 0.46, 95% CI 0.11-1.93). Conversely, atopic dermatitis with allergic sensitization increased the risk of asthma over sevenfold (RR 7.04, ). Atopic dermatitis and allergic sensitization had significant interactions on both the additive (RERI 5.06, 95% CI 1.33-11.04) and multiplicative (ratio of RRs, 5.80, 95% CI 1.20-27.83) scales in association with asthma risk. There was also a positive additive interaction between atopic dermatitis and allergic sensitization in their effects on food allergy risk (RERI 15.11, . Conclusions: Atopic dermatitis without allergic sensitization was not associated with an increased risk of asthma. In combination, atopic dermatitis and allergic sensitization had strong interactive effects on both asthma and food allergy risk at age 3. Background: In a post-marketing analysis last updated in July 2007, the FDA reported that an estimated 0.2% of patients suffered treatment related anaphylaxis and rare incidence of serum sickness. To substantiate this, the occurrence of treatment related anaphylaxis and serum sickness was assessed in one of the largest global allergy and asthma tertiary clinics. Methods: The original retrospective chart review of our database of Omalizumab administration was performed to collect data between 1998 and June 2014. This has been updated to include the recent data from July 2014 to June 2017. Data was collected on the number of patients receiving treatment, the number of injections received/ dose schedule of each patient, as well as the age and gender of each patient. Results: During clinical trials and with our post market experience, between 1998 and June 2017, over 50,000 injections of Omalizumab were administered to over 400 patients diagnosed with either severe allergic asthma or chronic idiopathic urticaria. No cases of anaphylaxis or serum sickness like symptoms were observed. Conclusions: Meticulous care was taken by our Omalizumab administration clinic to ensure optimal safety based on the emphasized warnings of anaphylaxis, as well as the indicated warnings and precautions for serum sickness. Data collected in this analysis observed no cases of anaphylaxis or serum sickness like symptoms in the treatment of patients with Omalizumab, during a period of 17.5 years, thus confirming the low incidence of both anaphylaxis and serum sickness. Background: We designed a written anaphylaxis plan called Canadian Anaphylaxis Action Plan for Kids (Kids' CAP) which incorporates validated pictograms with written instructions. Using a patient-centered approach, we aimed to assess the impact of the Kids' CAP on anaphylaxis recognition and treatment, and to determine its perceived usefulness. Methods: Prior to clinical validation, we assessed the readability and understandability metrics of the Kids' CAP using the Gunning Fog index (GFI), the Fry index, and the Patient Education Material Assessment Tool (PEMAT). During the clinical assessment phase, patients (12-17 years of age) and parents of patients (0-11 years of age) were taught and given the Kids' CAP during first visit with an allergist at two community clinics, or an anaphylaxis emergency department (ED) visit at a tertiary pediatric centre. The Newest Vital Sign tool was used to determine the baseline health literacy level of study participants. Three weeks later, we conducted a phone interview to assess their comprehension of anaphylaxis manifestations and management. We also used the Consumer Information Rating Form (CIRF) to measure the participants' perception of the usability, satisfaction, and usefulness of the Kids' CAP. Results: Two hundred participants completed the follow-up interview. The median age of patients was 3.95 years (IQR 1.4-9.2), and 104/200 (52%) were males. The written contents of the Kid's CAP matched grade 7 readability level. The mean CIRF score for usability and design quality were 23 (out of 25) (SD 2.6), and 25.1 (out of 30) (SD 2.5), respectively. The mean comprehension score was 11.2 (out of 14) (SD 1.7) with no significant difference between participants with and without previous experience with anaphylaxis, or high versus low literacy level.
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Conclusions:
The implementation of the Kids' CAP can improve patient's comprehension of anaphylaxis manifestations and treatment, which are critical components of ED management of anaphylaxis. Background: The recent rise in food allergy prevalence has led to an increase in the number of parents concerned about accidental exposure of their children to allergenic food. Our goal was to investigate the role of the school environment on food allergy emergency room visits. Methods: Visits to Canadian emergency departments for food and environmental/drug allergic and anaphylactic reactions were obtained from the Canadian Institute for Health Information (CIHI), based on the 2013-2014 National Ambulatory Care Reporting System. Reactions were defined in accordance to the ICD-10-CA diagnostic codes. Data was provided grouped by approximate school attendance ages into 3-5 (pre-school), 6-12 (primary school) and 13-18 (secondary school) years. Data was divided into day (9-16:59) and night (17-0:59). Allergic reactions to Environmental and Drug triggers were analyzed as control. p < 0.05 was considered as statistically significant assuming equal distribution. Chi squared analysis and T-testing (STATA14) were performed. Numbers shown are normalized by age categories and represent mean per hour over the span of the 6 months with full school scheduling. Results: During the study period, 2758 food and 3398 environmental/ drug visits were recorded. Significantly fewer food allergic reactions were recorded during the day than at night for preschool (5.17 ± 2.16 vs. 9.83 ± 4.46), elementary (2.875 ± 1.13 vs. 5.98 ± 2.53), and secondary school (4.65 ± 1.89 vs. 7.06 ± 2.35) age groups. Fewer events were recorded among primary school ages during the day than both preschool and secondary ages, while this difference was not significant at night. Environmental/drug allergic reactions showed the opposite trend, with fewer reactions at night during the day, and no differences between age groups during day or night. Conclusions: A structured environment may protect primary school aged children from food allergic reactions during daytime. In general, school-aged children visit the emergency room more frequently after school, which could inform recruitment for allergy studies. Background: The risk of developing anaphylaxis has been reported in multiple population-based studies, with estimates and definitions being highly variable. The aim of this systematically review is to synthesize the incidence, etiologies, and definitions of anaphylaxis worldwide. Methods: Following established guidelines, systematic review of records in any language obtained from multiple database searches (MEDLINE, EMBASE, Cochrane Register) through May 25, 2017 for population-based studies reporting on the incidence and elicitors of anaphylaxis and methodology used to identify and validate cases. Risk of bias and assessment of the certainty of evidence will be rated by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Results: Database searches yielded 1706 unique records, of which 245 were potentially relevant, and 91 are included for analysis. The range of reported incidence rates for anaphylaxis, stratified by geographic location, age, setting and definition will be reported. Methods of identification and validation of anaphylaxis will be reviewed, highlighting their relative merits and potential limitations. We anticipate that like most population-based research, the main limitation of these studies will be under ascertainment of events. If there is sufficient detail in reporting, we will synthesize the incidence and accuracy of specific causes of anaphylaxis, such as foods, drugs, insects, and idiopathic. Conclusions: The incidence of anaphylaxis through population-based research will be systematically reviewed, synthesized and assessed. These data, and a uniform case definition are critical to establish anaphylaxis risk estimates for patients and clinicians, as well as to inform future research and guidelines.
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Novel suspension medium for peanut and tree nut oral immunotherapy -Canadian pediatric private practice oral immunotherapy using NuT suspension (Canadian -PPPOINTS) Douglas P. Background: As the incidence of food allergies continues to rise, potential therapies are undergoing investigation. Oral immunotherapy (OIT) for food has been studied in the pediatric population in both phase 2 and ongoing phase 3 trials. Families are keenly interested in this approach of actively managing food allergy despite our lack of knowledge of long term outcomes. We sought to investigate the use of a novel suspension medium to desensitize patients with peanut and tree nut allergy. Methods: This is a retrospective review from 2014 to 2017 of OIT in a pediatric outpatient clinic. After initial evaluation, testing, detailed informed consent/assent and potential oral challenge, participants were given the opportunity to be desensitized to the foods of concern. This included peanuts, and multiple simultaneous tree nuts. Peanut and/or individual tree nut flours were suspended in Suspendit ™ medium and were given daily as sublingual/oral administration starting at 0.25 mg total nut protein and progressing up to 50 mg nut protein in suspension and then transitioned to actual weighed nut. Doses were increased in clinic on a biweekly basis. Results: Oral desensitization was successfully completed in a high majority of the 38 patients who initially enrolled ages 9 months to 17 years. The majority of individuals reported mild side effects. However, moderate to severe reactions were reported in several individuals during build up and maintenance requiring epinephrine use. Cofactors for reactions such as illness and compliance were identified. Side effects diminished with prolonged use. Skin prick testing decreased after being on maintenance therapy for 6-12 months. Conclusions: This is the first Canadian data to report on the safety and efficacy of pediatric oral immunotherapy in private practice for peanut and tree nut allergies. Suspendit ™ suspension medium allowed for safe and effective dosing titration of OIT for peanuts and tree nuts. Results: Among 29 children, the mean age at study entry was 11.9 years (SD 3.9) and the majority were male (58.6%). Co-morbidities included asthma (82.8%), seasonal allergy (48.3%) and eczema (27.6%).In total 8 children withdrew from OIT (27.6%). Among those, the mean number of anaphylactic reactions per patient was 14.1 (SD 18.2) versus 7.2 (SD 7.3) in non-withdrawals. On average, 0.6 (SD 0.9) reactions required epinephrine treatment in children maintained in the study versus 0.7 (SD 1.1) in withdrawals. Differences between both groups were statistically nonsignificant.Among 1060 AE, the majority were non-anaphylactic (75%). Of those, the majority occurred during the escalation phase (91.0%) and were categorized as mild (78.5% Background: Oral food challenges (OFCs) are considered the gold standard in food allergy diagnostic testing. Despite this, there is a lack of Canadian data regarding its implementation. We investigated how many allergists perform OFCs, number of OFCs performed, barriers that prevent more from being conducted, and possible solutions to these barriers. Methods: Surveys were sent to allergist members of the Canadian Society of Allergy and Clinical Immunology (CSACI). Questions included practice characteristics, number of OFCs conducted, barriers to conducting more OFCs, and solutions that would mitigate barriers. Results: Of the 205 CSACI allergists surveyed, 61 responded (response rate = 30%). Preliminary data showed 50 of the 61 respondents conducted OFCs (range = 1-60/month, median = 12/month, 66% perform 10 or more/month). There was no significant difference between number of OFCs performed and allergists' years of practice, or number of OFCs performed between allergists using a specific hospital OFC fee code and those using all other codes. Nearly all respondents agreed there was a need to conduct more OFCs, but barriers exist, with 74% of respondents choosing "lack of support staff", and 70% choosing "lack of time" as "moderately to extremely influential" barriers. The most influential solutions were "standard criteria for which challenges should be done in a hospital versus the community" chosen by 72% of respondents, and "patients agreeing to consume the food after a negative OFC", chosen by 70%. Conclusions: This is the first study to capture barriers and examine possible solutions to OFC implementation. Selection bias may be a limitation in this study since allergists who perform OFCs may be more likely to complete the survey. Results show that resources (support staff and time) to perform OFCs are lacking, and that standard OFC protocols and patient education around OFCs need to be explored as possible solutions to allow OFCs to be more accessible to Canadian patients. Background: Teens with food induced anaphylaxis (FIA) live with the unpredictable risk of reacting to, and potentially dying from something they eat. FIA results in considerable burden for teens, including stigma, marginalization, and the need for constant vigilance. Despite teen anaphylaxis rates in Canadian emergency rooms more than doubling in recent years, no published studies have focused exclusively on the teen experience living with FIA in Canada. At present, we lack the knowledge to recommend best practices in managing teens with FIA. Therefore, in this study we aim to create a detailed understanding of teens' lived experience of FIA in daily life. Methods: We combine van Manen's hermeneutic phenomenology with photovoice techniques to explore and interpret the lives of teens with FIA through their eyes, using their own words. Participants will include teens (age 12-19) living in Manitoba. Each teen will participate in 2 semi-structured interviews: the first will focus on lived experience, with photovoice images and techniques incorporated in the second interview. Interviews will be recorded and transcribed, and images retained for analysis. Both researchers will code and analyze data independently to identify meaning, relationships, and themes. Data collection and analysis will occur concurrently, informing the study as it progresses. Teens will be invited to join a Youth Advisory Committee (YAC) to discuss findings and inform knowledge translation efforts. Results: To be presented via traditional academic means (e.g. journal publications, conference presentations) and tailored education sessions for knowledge users, alongside initiatives determined in consultation with YAC members. Conclusions: This study fosters understanding, forming a base for future research to meet the healthcare needs of these teens and their families. Findings have potential to inform policy affecting teens with FIA, helping to focus change in priority areas and assist in health promotion for teens and families living with FIA. Background: Patient and caregiver knowledge of the symptoms and triggers of food allergy is key to successful management. To date, there have been no Canadian studies on this issue. We aimed to characterize patient and caregiver knowledge of food allergy in a Canadian setting. Methods: The Food Allergy Epinephrine Auto-Injector Study (FEAST) is an observational study on the dining experience of food allergic patients. Online surveys were administered to patients and caregivers in February 2015. Patients were identified from Food Allergy Canada's database. Among others, the survey contained questions on symptoms and triggers of food allergy. Results: There were 1165 respondents of the survey. 93.3% correctly identified the symptoms of an allergic reaction. Most knew that ingestion of small amounts of allergen could cause a reaction (92.6%). There was a high degree of understanding that removal of allergen from a plate is not sufficient to prevent reaction (93%). More respondents (48.8%) than not (45.5%) believed smell of peanut butter could cause a reaction. The majority correctly identified Health Canada's list of the ten most common food allergens: peanut (93.7%), treenuts (93.2%), shellfish and crustaceans (92.3%), egg (91.5%), milk (90.4%), wheat (84.1%), soy (81.2%), fish (77.3%), sesame (76.1%), mustard (57.3%), sulfites (not tested). There was a high degree of correct identification of uncommon causes of food allergy: apples (97.3%), chocolate (93.6%) coconut (94%), strawberry (77.4%), onion (98.6%), garlic (98.3%), pumpkin seed (98%).
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Conclusions:
The Canadian respondents had high recognition of the symptoms of food allergy. Knowledge of the common and uncommon food allergens was also good. Understanding of cross contamination as a cause of allergic reaction was similarly high. Lower rate of correct identification of mustard and strawberry as common and uncommon allergens respectively were seen. There was also a notable amount of misunderstanding that smell could cause a reaction.
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The use of oral immunotherapy for milk allergy in a Canadian pediatric private practice clinic Douglas P. Background: As the incidence of food allergies continues to rise, potential therapies are investigated. Oral immunotherapy (OIT) for food has been studied in the pediatric population for milk. We sought to investigate the use of oral milk immunotherapy to desensitize patients with milk allergy. Methods: This is a retrospective review from 2014 to 2016 of OIT in a pediatric outpatient clinic ages 5-13 years (mean 9.8). After initial evaluation, testing, detailed informed consent/assent and potential oral challenge, participants were given the opportunity to be desensitized to milk starting with 1 drop of 1:25 diluted milk in sterile water. Maintenance target dose was 250 mL of cow's milk. Doses were increased in clinic on a weekly-biweekly basis. A sublingual/oral immunotherapy approach was used. Those with asthma and prior severe reaction were not excluded.
Results:
Oral desensitization was successfully completed in 4/5 patients initially enrolled. One participant withdrew because of personal reasons. The mean length of time to target dose was 31 weeks. The majority of individuals reported side effects, most of which were mild, some requiring antihistamine use, and no moderate or severe reactions were noted. All participants had experienced prior anaphylaxis before enrollment. Epinephrine was not administered during OIT. Mean initial skin test size was 9 mm (range 8-10). Skin prick testing became negative in the patients tested after being on maintenance therapy for 12 months. Conclusions: This is the first Canadian study to demonstrate that oral immunotherapy can be safely and effectively used in a private practice setting for milk allergy in a pediatric population. Clinical presentation: Our patient had atopic dermatitis in infancy. At age three, extensive skin prick testing determined sensitization to multiple foods. The family subsequently avoided cow's milk, fish, shellfish, eggs, peanut and tree nuts. As an alternative to milk, he drank mainly unfortified juices and water. No further allergy follow-up occurred.At age 14 years, he presented to hospital with tetany in the upper and lower extremities. Investigations included: ionized calcium level = 0.60 mmol/L (1.1-1.3 mmol/L), parathyroid hormone level = 45.9 ng/L (1.5-7.6 ng/L), and vitamin D (25-OH) level < 10 nmol/L (75-200 nmol/L). Celiac disease and renal causes were excluded. A skeletal X-ray reported osteopenia. Allergy consultation determined an absence of past IgE-mediated reactions to any foods. Skin prick testing was positive to cow's milk, egg, peanut, tree nuts and shellfish, and negative to fish. Management and discussion: He received intravenous calcium, vitamin D supplementation (1000 IU/day) and a referral to a dietician. Oral food challenges are planned to clarify food allergy status. Potential long-term harm can occur when skin testing is performed at an early age without history of IgE-mediated reactions to foods, and when patients are lost to allergy follow-up. Sensitization alone does not indicate a food allergy. When age-appropriate, nutritionally replete substitutions are not offered, severe vitamin D deficiency can be a long-term sequelae of prolonged cow's milk avoidance. Vitamin D supplementation (400 IU/day) should be considered in cow's milk allergic individuals because of inadequate dairy intake.
Consent to publish:
Written informed consent to publish was obtained from the patient's guardians. Background: In 2015, Allergy Consensus Guidelines began recommending peanut introduction before age 12 months for high-risk infants in countries with high peanut allergy prevalence. They suggested that these infants may benefit from an allergist's assessment before peanut introduction. We evaluated if peanut allergy prevalence was different among infants who had peanut introduced before assessment versus infants who had peanut introduced after assessment. Methods: We screened infants born in 2015 and 2016 who were referred to Pediatric Allergy Clinic before age 12 months, regardless of the reason for referral. Children at high risk for peanut allergy because of egg allergy and/or moderate-severe atopic dermatitis were included. We compared the prevalence of peanut allergy among infants who were first introduced to peanut before allergy assessment versus infants who were first introduced to peanut after assessment. Data were analyzed by Chi square and Kruskal-Wallis tests. Results: Of the 42 infants at high risk for peanut allergy, peanut introduction data were available for 34: 13 (38.2%) had peanut introduced before allergy assessment, 13 (38.2%) had peanut introduced after assessment, and 8 (23.5%) did not have peanut introduced. Baseline characteristics were similar among the three groups: egg allergy (76.9, 61.5, and 50.0%, p = 0.21), moderate-severe atopic dermatitis (46.2, 76.9, and 75.0%, p = 0.14), age at first visit (11.1, 9.0, and 10.8 months, p = 0.31) and peanut sensitization (38.5, 46.2, and 50.0%, p = 0.60). For infants who had peanut introduced before and after allergy assessment, median age of peanut introduction was 8.0 versus 11.0 months (p = 0.017), peanut was introduced before age 12 months in 92.3% versus 61.5% (p = 0.068), and peanut allergy prevalence was 38.5% versus 38.5% (p = 1.0). Conclusions: Children introduced to peanut after allergy assessment had peanut introduced later but were as likely to be introduced before age 12 months. Peanut allergy prevalence was similar among infants introduced before and after assessment. Background: In medical ethics, the justice principle holds that when allocating care, patients in similar situations should have access to the same care. The recent opening of a publicly funded oral immunotherapy (OIT) program at our center, raised ethical issues as the demand for treatment was expected to significantly exceed its capacity. Criteria for patient selection had to be determined that would respect the justice principle and have high acceptability from patients, clinicians and managers. Methods: Using a Delphi approach with 3 iterations, a panel of 25 experts were asked to propose and validate prioritization criteria for OIT, and establish their respective weights based on a fictive scenario. The consensual weights were used to determine prioritization ratios for patient subgroups and design a system that would adjust in realtime to the prevalence of these subgroups within the waiting list. This system was submitted to the expert for approval. Results: The 25 experts that agreed to participate to the Delphi included 8 representatives of patient groups, 10 allergists (4 with experience with OIT), 3 allergy nurses, 2 administrative agents with experience managing tertiary care allergy referrals and 2 managers. In addition to validating the admissibility criteria, the participants reached a consensus on 4 main prioritization criteria and their prioritization ratio (PR):
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• Allergy to multiple food groups (PR = 2.53).
• Allergy to an ubiquitary food in its cooked form (wheat, soy, milk, egg) (PR = 2.74).
• Age less than 3 years (PR = 2.74) and age 4-7 years (PR = 1.54).
• Food allergy-related quality of life judged within 10% (PR = 6.86), 25% (PR = 3.06) and 50% (PR = 1.72) worst of the cohort.
Conclusions:
The system based on applying consensual PR to subgroup prevalence within waiting list was unanimously approved by a multidisciplinary expert group. The most frequently mentioned comment was that the PR system gave a real opportunity for less severe but admissible patients to benefit from the program, whereas traditional additive scoring system would de facto result in these patients never being seen, and were thus perceived as unfair. Background: While oral immunotherapy (OIT) is a promising new approach to treat food allergies, it is associated with significant costs, deriving mostly from frequent up-dosing visits, individual food dose preparation and supervision of home dosing reactions. About half of food allergic children react to over 300 mg of allergen protein content, which would allow them to tolerate small amounts of the food in their daily diet. Such patients with spontaneous partial oral tolerance (SPOT) could potentially benefit from progressive introduction of their allergen in their diet without the burden of classical OIT approaches. Methods: Charts from all patients with SPOT who underwent progressive allergen introduction after May 2012 were reviewed. Descriptive analysis was undertaken for patient demographic and clinical characteristics, reaction thresholds, food introduction dynamics (starting daily food dose and progression), and reaction rates at home and with up-dosing in the clinic. Results: Ninety-five (95) patients aged 1-18 years with SPOT underwent progressive daily introduction of their allergen in their diet during the studied period. Index foods included egg (23%), soy (3%), wheat (3%), milk (13%), sesame (3%), peanuts (46%) and tree nuts (8%). The average reactivity threshold was lowest for milk (725 mg of proteins) and highest for peanut (5763.78 mg of proteins). During an average follow-up of 1.5 years, the main symptoms reported by patients included oral symptoms (9%), urticaria (2%), eczema (2%), dyspepsia (2%) and cough (1%). No anaphylactic reaction was observed. Nine percent (9%) of patients had dose reduction at some point during the follow-up. At time of analysis, 80% of patients tolerated a daily dose that was higher than their initial reaction threshold. Patient satisfaction was very high. Conclusions: Progressive introduction of food allergen at home is well tolerated and could be a less costly approach than traditional OIT in patient with SPOT. Conclusions: Calgary has a lower rate of anaphylaxis than Montreal (difference − 0.12% (95% CI − 0.18%, − 0.06%). Food was responsible for 63% of cases in both sites. Peanut was the most common food allergen in Calgary versus shellfish in Montreal. Shellfish and dust mite allergy are strongly associated, and the absence of dust mites in Calgary potentially results in less shellfish allergy. Epinephrine administration was higher in Calgary, possibly because the Calgary study was conducted 4 years later and reflects increased awareness about anaphylaxis management. Introduction: Regulatory B-cells (Bregs) have been implicated in venom immunotherapy and their role is being actively studied in nonIgE-mediated food allergies and autoimmune diseases. No studies have examined the correlation between Bregs and IgE-mediated milk allergy, nor have the action of Bregs been examined in the treatment of food allergies with oral immunotherapy (OIT). Furthermore, there are currently no phenotypic, transcription factor, or lineage markers unique to regulatory B cells, making it a diverse and challenging focus of research. Programmed death-ligand 1 (PD-L1) is one of the surface molecules described on Bregs. PD-L1 is an inhibitory ligand expressed on antigen-presenting cells and tumor cells. Methods: Peripheral blood mononuclear cells were isolated from plasma of milk-allergic children undergoing milk OIT, at baseline and at the end of escalation phase. The cells were cultured for 72 h in various conditions and stained for CD19, CD27, CD38, CD5, CD24, PD-L1, and intracellular IL-10. Conditions included CpG-B, anti-IgM/ IgG, and anti-CD40, IL4, IL21. Milk proteins (casein, α-lactalbumin, β-lactoglobulin) were added to some conditions as specific antigens. Statistical analysis was done using the Wilcoxon matched-pairs signed rank test and a p-value less than 0.05 was considered significant. Results: An interim analysis showed a significant increase in 6 patients in the CD19 dim PD-L1
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+ CD38 + population at the end of escalation phase in 3 conditions: CpG-B/anti-IgM/IgG/anti-CD40, anti-CD40/IL4/ IL21, and anti-CD40/IL4/IL21 plus milk proteins. The median percentage difference between baseline and end of escalation phase was 8. 35, 4.49, and 7 Background: Venom triggered anaphylaxis cases (VTAC) represent 4.1% of adult anaphylactic reactions and account for the most severe reactions. The aim of this study was to collect data on patient characteristics associated with VTAC and to compare the management of these cases in both the pre-hospital and emergency department (ED) setting in Canada to the clinical guidelines. Methods: The Cross-Canada Anaphylaxis Registry (C-CARE) enrolls anaphylactic cases presenting to EDs and out-of-hospital emergency medical services (EMS). We utilized C-CARE to identify VTAC that presented to EDs at the Montreal Children's Hospital and Sacré-Coeur Hospital, and to EMS in Western Quebec from June 2013 to May 2017. ED physicians and EMS paramedics documented characteristics, triggers, and management using standardized forms. Consenting patients were contacted annually regarding long-term management. Univariate and multivariate logistic regression were used to identify factors associated with epinephrine treatment and severe reactions. Results: Between June 2013 and May 2017, 115 VTAC were identified, of which 60% were prospectively recruited. Epinephrine was administered to 63.5% (95% CI 53.9, 72.1%) of all VTAC by a healthcare professional. Reactions occurring at home were more likely managed without epinephrine (OR 1.27 [95% CI, 1.09, 1.47]). Severe reactions were more likely to occur in patients receiving regular daily nonsteroidal anti-inflammatory drug treatment (OR 1.45 [95% CI, 1.03, 2.07]) and while at home (OR 1.25 [95% CI, 1.04, 1.49]) while controlling for age, beta-blocker use, reactions occurring during exercise and administration of anti-histamines in-hospital. Limited follow-up data was obtained to due low response rate; however 29 patients were successfully contacted of which 89.7% (95% CI, 71.5%, 97.3%) were prescribed an epinephrine auto-injector, 44.8% (95% CI, 27.0%, 64.0%) saw an allergist who confirmed the allergy, and 27.6% (95% CI, 13.4%, 47.5%) received immunotherapy. Conclusions: Clinical guidelines strongly encourage that VTAC be referred to an allergist for confirmation of allergy and desensitization treatment, however less than 50% of patients had confirmation and less than a third of those confirmed received immunotherapy. Given that the guidelines are not adhered to in clinical practice, several knowledge translation solutions should be explored and implemented in order to close this knowledge-to-action gap. Allergy Background: The barrier-derived cytokine Interleukin-33 (IL-33) is a critical regulator of pathological processes in atopic dermatitis. This alarmin signals through interleukin-1 receptor-like-1 (ST2) receptor resulting in a Th2 immune response. We examined the expression of IL-33 and ST2 in skin following an intradermal allergen challenge in patients with atopic dermatitis. Methods: Patients with moderate to severe atopic dermatitis who developed a late cutaneous response to intradermal challenge, with common airborne allergens were recruited. Patients withheld oral steroid (8 days) and other immunosuppressive medications (4 weeks) prior to challenge. Allergen and saline control were injected intradermally on the patient's back. At 24 h post-challenge, the size of the wheel and flare was measured and a punch biopsy was obtained. Biopsy tissue was formalin-fixed, paraffin embedded, and stained with antibodies to IL-33 and ST2 for immunofluorescence microscopy. Regions of interest (ROI) highlighting the epidermis and dermis were selected and images were obtained using an upright Nikon microscope. The thresholding tool in the NIS-element software was set to pick up the radius of 6 pixels from selected channels corresponding to the intensity value of these pixels. All pixels in the image of similar intensity value were highlighted. Data was exported to excel showing the number of objects and the mean intensity of each channel in the selected ROI. Results: Data are presented for 4 patients. When compared to saline, intradermal allergen increased the number of cells/mm 2 expressing IL-33 by approximately 30% in the dermis (p = 0.02) and epidermis + dermis (p = 0.03). In the epidermis, the number of cells/mm 2 expressing IL-33 increased in 3 of the 4 patients studied (p = 0.09). No significant changes in ST2 expression were observed, due to the small sample size. Conclusions: Our data supports the role of IL-33 in acute allergeninduced inflammatory processes in atopic dermatitis.
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Bicyclic petasite sesquiterpenes potentiate peroxisome proliferator activated receptor gamma activator and inhibit dendritic cell maturation and activation Narcy Arizmendi Background: The anti-inflammatory role of many plant derivatives is not fully understood. There is evidence that a family of plant derivatives, the petasite sesquiterpenes, can regulate the immune system through dendritic cell (DC) targeting. DC activation induces their expression of class-II major histocompatibility complex (MHC) and co-stimulatory surface molecules, as well as migration into secondary lymphoid organs, where they activate naïve T-cells. To better understand the anti-inflammatory effects of petasite sesquiterpenes, we focused on their activation mechanism involving peroxisome proliferator activated receptor gamma (PPARγ). PPARγ is a transcription factor that inhibits inflammatory responses and induces DCs to acquire a mucosal phenotype. Since mucosal DCs are central in innate immune responses, we hypothesized that sesquiterpenes would inhibit DC maturation and activation via the PPARγ pathway.
Methods:
We generated mouse bone marrow-derived DC (BmDC) in media supplemented with GM-CSF+IL-4. BmDC were treated with bicyclic petasite sesquiterpenes in the presence or absence of PPARγ agonists, followed by overnight activation with LPS. BmDC were harvested and analyzed for surface expression of co-stimulatory molecules CD80 and CD86, by flow cytometry, and pro-inflammatory cytokine production, by commercial ELISA. Results: Bicyclic petasite sesquiterpenes downregulated the expression of the co-stimulatory molecules CD80 and CD86 and proinflammatory cytokines of LPS-activated DCs. We observed differences in the downregulation of CD80 and CD86, and in TNF, IL-6 and IL-12p70 release when LPS-activated DC were pretreated with petasite sesquiterpenes or combinations of petasite sesquiterpenes and PPARγ agonists. Conclusions: Bicyclic petasite sesquiterpenes inhibited the maturation and activation of DC, and this inhibitory activity was enhanced in the presence of PPARγ agonists. Studies are underway to determine the intermediary molecules involved in DC inhibition. Background: Breast milk feeding has many beneficial effects, including a reduced risk of food allergy. Cow's milk also contains several regulatory molecules, such as TGF-β and vitamin A, which could enhance oral tolerance. Toll-like receptor 2 (TLR2) activation by pathogen products or their analogues can lead to tolerance disruption. Soluble tolllike receptor 2 (sTLR2) acts as a decoy receptor and is found in both human and cow's milk; however, its role in oral tolerance is unknown. Hypothesis: We hypothesize that sTLR2 can block tolerance disruption by TLR2 ligands found in food or microbes. Methods: Oral tolerance was assessed in wild-type and TLR2-deficient mice through analysis of antigen-specific antibody responses after OVA feeding and a systemic antigen challenge. The ability of cow's milk to block the anti-tolerogenic effects of a TLR2 activator (PAM3CSK4) was assessed. Tolerance to OVA was also assessed in mice that were nursed by WT or TLR2 −/− dams. The impact of cow`s milk on development of antigen-specific Treg cells and tolerogenic dendritic cells was also determined. Results: Oral administration of antigens over 1 week induced the development of tolerance, independent of TLR2 expression. Tolerized mice produced 5.8-fold less allergen-specific IgE than controls (n = 15). Soluble TLR2 was detected in cow's milk and in commercial baby formulas (range 15-35 ng/mL). Interestingly, cross-fostering of pups by WT dams resulting better oral tolerance induction to OVA compared to pups nursed by TLR2 −/− dams. Furthermore, cow's milk feeding was also able to enhance the development of ovalbumin-specific Treg cells and tolerogenic-dendritic cells significantly in Peyer's patches and mesenteric lymph nodes of mice. Conclusions: Our results suggest an important role for cow's milkregulatory molecules and sTLR2 in the development of oral tolerance, which could inform both allergy prevention and treatment strategies. Background: Neuroinflammation is a specific immunological reaction in the central nerve system and is distinct from peripheral inflammatory responses. It is induced by microglia, which is a resident phagocyte in the brain. Neuroinflammatory response is a defense system against exogenous antigens, but chronic neuroinflammation is involved in various neurodegenerative disorders. Hesperetin is present in the peel of citrus as one of the flavonones. In previous studies, hesperetin has been shown to have anti-inflammation, anti-cancer and anti-oxidant effects. However, the anti-neuroinflammatory effect of hesperetin on microglia is not well known. Methods: BV-2 murine microglia cell line was used in this study. Cytotoxicity of heperitin on BV-2 was measured by MTT assay and NO production was evaluated by Griess assay. Expression of pro-inflammatory genes and signal transduction protein were determined by RT-PCR and western blot analysis, respectively. Cytokine release was determined by ELISA. Results: Heperetin reduced the LPS-induced no production at noncytotoxic concentration. Furthermore, hesperetin effectively inhibits mRNA expression of pro-inflammatory molecules including TNF-α, iNOS, and IL-6 and IL-1β, and cytokines, IL-6. Hesperetin inhibited the phophorylation of p38 and ERK in LPS-activated BV-2 microglia. Conclusions: These results suggest that hesperetin has an anti-neuroinflammatory effect on LPS-activated BV-2 murine microglia through the suppression of p38 and ERK phosphorylation. Background: The role of mast cells (MC) in host defences against influenza A virus (FluA) is incompletely understood. We found that MC were resistant to productive FluA infection and suppress viral propagation in airway epithelial cells (AEC) in co-culture systems. We hypothesized that MC interact with AEC to produce a factor(s) that enhances antiviral capabilities, therefore reducing viral replication and release of infectious particles and enhancing AEC survival. Methods: Our experimental model to investigate MC and AEC interaction during FluA infection involves a co-culture system with AEC (Calu-3) cultured on the membrane insert in the top chamber, and human MC (LAD2) in the bottom chamber. FluA infection was achieved by exposing AEC to A/PR/8/34 (H1N1; 0.04 MOI [multiplicity of infection]). Hemagglutination assay was used to assess viral propagation 3 days post infection. Supernatants of post-FluA experienced AEC-MC cocultures were collected for further investigation. Supernatants were treated to 65 and 100 °C for 30 min to investigate heat lability of antiviral activity. Fractionation of supernatants were performed using Centricon size exclusion filters (10 kDa). Ion exchange columns are used to further fractionate supernatant by molecular charge. Results: In the presence of MC, AEC were found to release 3-fold less FluA particles. Supernatant from a FluA experienced AEC-MC co-culture exhibits an antiviral effect against FluA in AEC. Heat treatment of the supernatant suggest that the antiviral effect is sensitive to 100 °C but not 65 °C. Fractionation approaches suggest that the antiviral effect is larger than 10 kDa. Preliminary data from ion exchange suggest that anti-viral activity has a high net positive charge. Conclusions: FluA experienced co-culture supernatant has antiviral activity mediated through a soluble factor(s) against FluA infection in AEC. Identification of the anti-viral factor(s) may foster novel approaches to enhancing FluA vaccination and therapeutic strategies. these cells in the pathogenesis of AD. This study aims to quantify EoP in the allergen induced late cutaneous response. Methods: Subjects with severe AD and a positive allergen prick test were recruited (n = 4). After 8 days of systemic steroid washout, intradermal challenge was performed with allergen and saline control. The late cutaneous response was measured at 24 h post challenge and biopsied. A 4 mm skin biopsy was formalin-fixed, paraffin embedded and stained with hematoxylin and eosin for eosinophils. Immunofluorescence staining was performed using fluorochrome linked antibodies to CD34-FITC, IL-5Rα-Cy5, and Von Willebrand factor-TRITC. Using Nikon Imagine Software Analysis, the papillary dermis was examined for EoP (CD34+/IL-5Rα+) cells that were Von Willebrand negative. A paired t-test was performed on the data.
A52 Examining the impact of TLR2 and cow's milk on oral tolerance development
A55
Mast cells enhance resistance against influenza A in epithelial cells
Results:
We identified the presence of both CD34+/IL-5Rα+ cells and mature eosinophils in skin biopsies with perivascular organization. There was a significant increase in EoP (p < 0.05) and mature eosinophils (p < 0.05) 24 h post-allergen compared to diluent control. Conclusions: Intradermal allergen challenge induces an increase in eosinophil lineage-committed progenitor cells and mature eosinophils in atopic dermatitis skin. Local in situ maturation may play a role in development of tissue eosinophilia in patients with atopic dermatitis.
Background:
Omalizumab is an anti-immunoglobulin E approved for the treatment of chronic spontaneous urticaria (CSU). Although its efficacy profile against CSU has been well documented in the literature, fewer reports have focused on chronic inducible urticarial (CindU). Methods: Patient charts were reviewed at the allergy and immunology department of the University of Montreal for cases of urticarial treated with Omalizumab. In this patient population with a diagnosis of chronic urticarial, only 8 corresponded to CindU and were included in this case series. Patients were started at a dosage of 300 mg every 4 weeks with further adjustments of dosage or frequency depending on the symptomology reported during follow-up visits. Response to treatment was graded with the Urticaria Activity Score (UAS7) ranging from 0 to 42 and Chronic Urticaria-Quality of Life (CU-QoL) ranging from 23 to 115. Results: CindU cases presented in different forms (cold, delayed pressure, solar, dermographism, cholinergic). From 8 patients, 3 remained on the initial treatment regimen, 1 was allowed to lower the dose to 150 mg and 4 required an increase in dosage or frequency, of which 3 received more than 600 mg. UAS7 scores ranged from 0 to 11 with a mean of 3.9 and a median of 2.0. CU-QoL scores ranged from 23 to 34, with a mean of 27.3 and a median of 25.5. When results were considered in function of the modified physician global assessment, 5 patients measured as clear to almost clear and 3 as partial responders. No patients showed limited or no response to treatment. Side effects were minimal. Conclusions: In conclusion, we report 8 cases with various types of chronic inducible urticarial that safely and satisfactorily responded to Omalizumab. Dosage and frequency were adapted to patients' symptomology. This flexibility helped patients to achieve complete to partial response to treatment. Background: Hymenoptera stings are a major cause of fatal anaphylaxis in children. Accelerated venom immunotherapy (VIT) schedules are more convenient and offer faster protection than conventional VIT. Although well studied in older children and adults, safety data in very young children is sparse. Methods: Between 2013 and 2016, 12 patients aged 16 months to 6 years received rush (n = 6) or ultrarush (n = 6) VIT at the allergy clinic of the Ste-Justine Hospital Center. Patients' mean age was 5 years, and 9 of the 12 (75%) were boys. At initial insect sting, 1 patient (8%) had a grade 1 reaction, 9 (75%) had grade 2 reactions, and 2 (17%) had grade 3 reactions as per Brown's criteria. All patients had at least one positive skin test to standardized venom extracts of bee, wasp, yellow jacket, yellow hornet, and white face-hornet (Jubilant HollisterStier LLC, Spokane, Washington, USA). Four out of 12 (33%) were administered rush or ultrarush VIT to mixed vespid, 6 of the 12 (50%) to mixed vespid and wasp, and 2 of the 12 (17%) to bee venom. We systematically premedicated all patients with antihistamines 1 h before the desensitization. Patients undergoing the ultrarush protocol were additionally premedicated with prednisone (1 mg/kg) to reduce delayed local reactions. All of the children were observed up to 2 h after the last injection. Results: Out of the 12 patients, none had any systemic reactions during buildup and maintenance doses. Only local reactions less than 10 cm were reported. One patient was restung and did not present any reaction during maintenance doses. Conclusions: Although this cohort represents a small amount of patients under the age of 6, they support the conclusion that rush and ultrarush VIT schedules are safe in this very young age group. Background: Rituximab is a monoclonal antibody targeted at CD20. It is used in chemotherapeutic regimens in several malignancies, as well as in a variety of autoimmune diseases, given its effects on B cells. Often, if a patient develops allergy to rituximab there are no alternative treatments, or the alternative is not as effective. There are published protocols for rituximab desensitization available but we were not able to find any case reports of their use in Canada. Case presentation: Patient 1 is a 29 year old female with a longstanding history of systemic lupus erythematosus (SLE), complicated with hypertension and significant lupus nephritis. The patient had failed multiple therapeutics for SLE and was doing well on rituximab, until she developed Type 1 and Type III hypersensitivity to the drug. With pre and post-medications she was successfully desensitized to rituximab, using a 12-step protocol. Patient 2 is a 70 year old female who presented with urticaria and respiratory symptoms during rituximab infusion for management of eosinophilic granulomatosis with polyangiitis. The patient was successfully desensitized to rituximab, using a 12-step protocol. Both patients were managed in an Intermediate Care setting as inpatients. Discussion: In our patients, rapid desensitization to rituximab was well tolerated. The protocols were successfully completed. For one patient, desensitization was successful in preventing Type I and Type III hypersensitivity. For one patient, the first desensitization produced mild symptoms. Subsequent desensitizations have not produced any significant reactions. There are some challenges in arranging inpatient beds for these desensitizations, which has affected the timeliness of their drug dosing. A multidisciplinary approach was necessary to establish a protocol for our institution. Conclusions: Rituximab desensitization can be safely done in a monitored setting with close supervision by an allergist. Background: Hereditary angioedema (HAE) is a rare disease that has significant morbidity and may be potentially fatal due to airway obstruction. Our study aimed to determine how Canadian physicians diagnose and treat HAE. Methods: A survey was designed to determine HAE practice patterns amongst Canadian physicians. These physicians were identified by sending the survey to members of three physician organizations: the Canadian Hereditary Angioedema Network, the Canadian Society of Clinical Immunology and Allergy, and the Canadian Hematology Society. Results: Thirty-six physicians responded to the survey. Thirty-four physicians were included in the analysis. The majority of referrals to HAE treating physicians were from family and emergency room physicians. The most common sites of swelling reported by patients to physicians were facial, peripheral and abdominal. A mean of 53.9% of HAE-Type 1 and II patients and 53.4% of HAEnC1INH patients were on long term prophylaxis. A mean of 41.9, 19.4 and 93.5% of respondents had some patients on danazol, tranexamic acid and C1-inhibitor respectively. The majority of physicians felt severity and frequency of attacks were the most important determinants in deciding when to use prophylaxis. A mean of 88.2% of physicians used C1-inhibitor to treat acute attacks and 79.4% used icatibant. A mean of 91.4 and 94.3% of respondents felt very or extremely confident using C1-inhibitor for prophylaxis and for acute attacks respectively. A mean of 71.4% of physicians felt very or extremely confident in using icatibant. All respondents were aware of HAE guidelines. Respondents felt a further need for guidance when managing HAE in pregnancy, and pediatric patients. Conclusions: Physicians are using guidelines to support their practice, and using agents suggested by guidelines with confidence. C1-inhibitor is being used widely for prophylaxis, as well as acute treatment of attacks along with icatibant. However, certain special patient populations may require additional focus in future guidelines. Background: Macrolides are commonly used antibiotics in children, however there are no standardized skin tests available for diagnosis of allergy. While up to 3% of children report reactions to macrolides, it is not clear how many have a true allergy. Our aim was to assess the risk of macrolide allergy in patients through the use of a graded oral challenge. Methods: All children referred to the Montreal Children's Hospital for potential antibiotic allergy were recruited for the LAACTAM study between March 2013 and 2017. A standardized survey with questions on treatment, symptoms, and associated factors was filled and an oral challenge (10 and 90% of the oral dose) was conducted at the clinic visit. The patients were contacted annually to query on subsequent antibiotic use and associated reactions. Multivariate logistic regression was used to estimate factors associated with a positive oral challenge. Results: Seventy-seven patients with a reported allergy to macrolide antibiotics were recruited, with 79.2% (95% CI, 71.4%, 88.5%) reporting a reaction to clarithromycin and 19.5% (95% CI, 11.7%, 28.7%) to azithromycin. The majority of the reactions were isolated to the skin and occurred within 3 days of starting treatment. Among 68 patients who underwent an oral challenge, 3 patients (4.4% [95% CI, 1.5%, 9.4%]) had a positive challenge, of which all were immediate reactions. A positive oral challenge to a macrolide antibiotic was associated with older age (OR 1.03 [95% CI, 1.01, 1.04]) while adjusting for sex, type of macrolide, history of known food allergy, drug allergy, and asthma. Among the 65 patients with negative oral challenge eligible for follow-up, 48 (73.8%) patients responded. Of the contacted patients, 15 (31.3%) reported macrolide antibiotic use and 1 patient (6.7% [95% CI, 0.3%, 34.0%]) reacted to subsequent treatment.
A61 Rush and ultrarush venom immunotherapy in very young children
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Conclusions:
Graded oral challenges can be used to safely diagnose macrolide antibiotic allergy. The risk of subsequent reaction among those with a negative challenge is almost 7%. Guidelines establishing the diagnosis of macrolide allergy are required to appropriately manage these patients. Background: Individuals with atopic disorders tend to have a decreased ratio of Th1 to Th2 cells, known as a "Th2 shift". The dynamic balance between Th1 and Th2 cells in combination with their functionality in early life has not been thoroughly investigated, and may serve as an important predictor of atopic disease. We investigated this prospect by examining cytokine production of newly polarized Th1 and Th2 cells from umbilical cord blood mononuclear cell (CBMC) samples from mothers with and without self-reported allergic disease. Methods: CBMC samples were collected and cryo-preserved from consenting mothers with self-reported allergy (high atopic risk (HR) n = 4) or no allergy (low atopic risk (LR) n = 3). Non-adherent mononuclear cells were isolated from thawed samples and cultured for 7 days under Th1 (Interleukin (IL) 12, IL-2, and anti-IL4), Th2 (IL-4, IL-2, and anti-IL-12), and non-polarizing (IL-2, anti-IL-4 and anti-IL-12) conditions. Culture supernatants were extracted and cytokine concentrations were quantified via Bio-Plex Pro ™ Human Cytokine 17-plex Assay. Results: IL-1β, IL-7, IL-8, IL-12, IL-17, IFN-γ, and TNF-α were significantly increased in Th1 cultures when compared to the Th2 polarizing condition (all p < 0.05). Significantly elevated IL-5 and IL-13 levels were observed in Th2 supernatants versus Th1 supernatants (all p < 0.05). HR participants generated numerically higher levels of IL-8 and IL-10 (p = 0.58 and p = 0.21 respectively), and decreased levels of IFN-γ (p = 0.19) when compared to LR counterparts.
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Conclusion:
The polarization culture conditions induced skewing towards a Th1 or Th2 cell phenotype with respect to cytokine concentrations. Given the small sample size of HR and LR participants, only weak trends for cytokine secretion were observed. Experiments with additional participants will improve power and confirm reproducibility of results in order to further address the potential of cytokine profiling in early life as a predictor of atopic disease. pregnancy ensued, IVIg was given monthly until 32 weeks. We prospectively followed patients during pregnancy and 1 month after delivery to determine the efficacy and safety of IVIg. Results: 15 patients were included. 13/15 (86%) have delivered healthy offspring; 2/15 (13%) failed their ET. In the subgroup analysis, successful outcomes occurred in 7/9 (77%) patients with primary RIF, 2/2 (100%) with secondary RIF, 3/3 (100%) with primary PRL and 1/1 (100%) with secondary RPL. IVIg related side effects included 6/15 (40%) reports of mild post-infusion headaches; one patient developed hypotension and chills during her first IVIg infusion but tolerated scIg. IVIg was discontinued prematurely in 2 patients, one because of hospitalization for renal colic and another developed prolonged hypotension at needle insertion. Obstetrical complications were reported in 2 patients, one delivered prematurely at 34 6/7 weeks because of HELLP syndrome, another developed preterm labour at 27 weeks but delivered a healthy child at term. There was one fetal anomaly reported; one child was born with mild benign hydrocephalus. Conclusions: Our IVIg protocol appears to be safe and may be effective for patients with suspected IMRF undergoing IVF and our results justify the need for a properly designed RCT. Background: Primary immunodeficiency diseases (PIDs) represent a significant collection of immune system disorders that increase susceptibility to infection, which in some cases are serious or lifethreatening. Patients with PID often require immunoglobulin G (IgG, commonly referred to as Ig) replacement therapy to prevent infections and associated comorbidities. PID treatment, in addition to symptoms and associated social and emotional impacts, has a significant impact on patients' quality of life (QoL). Methods: The authors conducted a cross-sectional survey to measure health-related QoL in a cohort of patients with PID. Eligible participants were identified through the Canadian Immunodeficiencies Patient Organization (CIPO). The questionnaire consisted of 61 questions that covered patient-reported outcomes including diagnosis, QoL, treatment regimes, and communication. Results: Surveys were returned by 149 patients with PID. Participants conveyed significant impact on QoL including personal, occupational, financial, emotional, and social impacts as a result of PID symptoms, risks, and treatment logistics, limitations, and side effects. The most common diagnoses were related to B-Lymphocyte disorders (60.4%). Common treatments include intravenous immunoglobulin (IVIg; in hospital) and subcutaneous immunoglobulin (SCIg; at home), in addition to antibiotics and antifungals as required. Respondents reported feeling "average" before treatment on a scale of 0-10 (mean 5.46 ± 2.23) with increased health after treatment (mean 6.66 ± 2.32). Respondents felt current treatment was convenient (mean 8.22 ± 1.94) and were comfortable with self-infusions (mean 6.96 ± 3.46). Conclusions: Patients with PID are not uncommon in the Canadian community, and in these patients PID is associated with a significant impairment in QoL. Experiences range with regards to a particular treatment's advantages and disadvantages, cost, travel, and convenience. Respondents hope to achieve improved QoL through the following solutions: better treatment, improved infusions, gene modification, more research and clinical trials, a cure, and education and outreach. Improved financial, medical, and social supports were also requested. Background: Chronic idiopathic urticaria (CIU) is characterized by wheals and itching for at least 6 weeks with no identifiable cause. Previous studies have suggested a relationship between female gender, asthma and CIU, but little is known about the predictors of prognosis. The purpose of this study was to determine the predictors of disease outcome for patients with persistent CIU. Methods: This was a retrospective chart review of patients 18 years of age and older with persistent CIU (at least 3 clinic visits) seen in the Outpatient Allergy Clinic at Kingston Health Sciences Centre. Patients exhibiting symptoms of physical urticarias were excluded. Patients' demographics, clinic visits, disease duration and outcome, comorbidities, angioedema, triggers, allergies, medications used, and results of work up were recorded. A two-level disease outcome was used, where "controlled" was defined as urticaria-free patients, on or off medication. Those who relapsed after a period of remission or had persistent symptoms despite medications were considered "uncontrolled". Analyses included Chi square tests, independent samples t-tests, and a multivariable logistic regression. This study was approved by Queen's University Ethics Committee. Results: Of the 98 patients included, 83% (81/98) were females. The average age, duration of disease, and number of clinic visits were 51.18 ± 15.12 years, 45.13 ± 69.9 months, and 4.63 ± 2.61, respectively. There was a trend between age and disease outcome, as prognosis was worse in younger patients (p = 0.077). A greater proportion of males obtained control of their disease (82.4%) as compared to females (64.2%) (p = 0.147). Female patients used significantly more medications then males to control their symptoms (2.77 vs 2.0, p = 0.026). Patients with co-existing asthma experienced significantly worsened outcomes as compared to non-asthmatics (p = 0.04).
A69 Predictors of prognosis for chronic idiopathic urticaria
Conclusions:
In adults with persistent CIU, younger female asthmatics were less likely to gain control of disease. Physicians should have a lower threshold for escalating treatment strategies for this patient population.
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Phenotypes, endotypes and biomarkers of hypersensitivity reactions to 16 monoclonal antibodies: Management with desensitization in 104 patients Ghislaine A.C. Isabwe and efficient avenue for their re-introduction. Our objective is to propose a new classification for HSRs to mAbs and provide new insight into their management with desensitization. Methods: We reviewed the characteristics of the presentation of initial HSRs for 104 patients, skin testing, biomarkers and the outcomes of their management with 526 desensitizations. Results: The initial reaction phenotypes included type I (IgE/non IgE mast cell activation) in 65 (63%), cytokine-release in 14 (13%), mixed reactions (Type I/cytokine) in 22 (21%) and delayed type IV in 3 (3%) patients. Skin testing was performed for 10 mAbs in 58 patients. A positive skin test was associated with severe initial reaction (p-value 0.0088). IL-6 was elevated in 8 patients, correlated with cytokine storm phenotype. Tryptase was elevated in 1 patient. There were no HSR during 404 (76.8%) desensitizations; when reactions occured, they were type I in 39 (32%), cytokine storm in 64 (52.5%), mixed in 14 (11.5%) and delayed type IV in 5 (4%). All but one patient safely completed their desensitization and received their target dose. Conclusions: A new proposed classification for HSRs to mAbs is provided based on the presentation and includes 4 phenotypes; type I (IgE/non-IgE mast cells activation), cytokine storm, mixed (type I/ cytokine release) and delayed type IV reactions. Endotypes were confirmed by tryptase and IL-6. Skin testing is a valuable tool in assessing HSRs to mAbs. Management with desensitization provides safe and effective re-treatment options. Precision and personalized medicine should be applied to patients with HSR to mAbs. Background: Mast cells play a key role in asthma. The release of preformed mediators, generation of lipid mediators, and production of cytokines, such as GM-CSF, contribute to inflammation and bronchoconstriction. Asthma exacerbations are often associated with respiratory viral infections. Severe asthma is also associated with reduced production of type I and III interferons (IFNs). Human mast cells have been described as an excellent source of IFNs [1] . Therefore, this study investigated the impact of concurrent FcεRI-mediated activation and viral infection on mediator production by human cord blood-derived mast cells (CBMCs). Methods: CBMCs were sensitized with IL-4 (10 ng/mL) and IgE (2.5 µg/ mL), and then activated with 2 µg/mL anti-IgE (n = 3). In some experiments, sensitized CBMCs were infected with reovirus (5 MOI) prior to activation with anti-IgE (n = 2). FcεRI expression was measured by flow cytometry. Degranulation was assessed via a β-hexosaminidase assay. IFNA2, IFNL1 and GM-CSF mRNA expression were assessed by qPCR and normalized to the reference gene HPRT. Results: IgE-sensitized CBMCs exhibited increased FcεRI expression (51.5%) compared to unsensitized controls (0.2%), and activation with anti-IgE induced degranulation at 30 min (34.2% vs 10.5% in controls). GM-CSF mRNA expression at 24 h was enhanced 7.122-fold by FcεRI activation, 12.67-fold by reovirus infection, and 55.15-fold by concurrent activation of these pathways compared to non-activated controls. IFNA2 and IFNL1 expression was also induced by reovirus infection. However, substantial donor variation in IFN responses to combined viral and IgE-mediated activation was observed. Conclusion: Our preliminary data suggests that reovirus infection of IgE-activated human mast cells synergistically enhances FcεRI-induced GM-CSF gene expression, but may have a more donor-dependent effect on viral-induced IFN production. Background: Idiopathic angioedema (IA) is a form of angioedema in which no known cause can be found. Phenotypically it is divided into histaminergic angioedema which responds to antihistamines, whereas non-histaminergic does not. Studies on the natural history and long term outcomes of idiopathic angioedema are lacking. Methods: Charts of patients with angioedema from an allergist office were reviewed. Patients over age 19 with an initial presentation of IA were recruited to the study. Telephone surveys were conducted to obtain data including demographics, disease characteristics and treatment. Results: 29 patients participated in the survey. Median age of disease onset was 45 years. Most patients reported attacks lasting less than 24 h. Body parts affected include lips (72%), eyelids (69%), tongue (66%), other facial structures (59%), extremities (41%), airways (38%) and trunk (21%). 59% feel attacks have become less frequent, 45% less severe and 31% shorter over time. 2 patients developed urticaria. 24% of patients report having had a life threatening event. One required intubation. 66% of patients presented at least once to the ER. Antihistamines are the most commonly prescribed treatment in the ER (79%). 53% received epinephrine. 84% responded to treatment. 34% are taking prophylactic antihistamines and 41% take them as needed. 74% of patients find antihistamines effective. 7/29 patients have not had an attack in the last 12 months and do not currently take antihistamines. Patients report stress, viral illnesses, alcohol, NSAIDS, pressure, insect bites and food additives as potential triggers. Conclusions: Idiopathic angioedema is a chronic illness with variability in frequency and duration of attacks. Angioedema may affect any body part but most commonly affects facial structures. Only a minority of patients will enter remission (no attacks in 12 months) but most patients improve symptomatically over time. Patients perceive antihistamines to be effective prophylactically and as needed. Background: VHCs are medical devices that are recommended by Asthma and COPD guidelines to be used with pMDI as a delivery system. VHCs improve medication delivery and reduce oropharyngeal deposition of medication; this is reflected in the fine particles mass (FPM, 1.1-4.7 µm) that reaches the airways of the lungs. The significant role of the VHC in drug delivery was acknowledged by the European Medicines Agency (EMA) in their recommendation that pMDI manufacturers should nominate at least 1 named VHC during clinical safety and efficacy studies. It also recommends if a VHC is to be substituted by an alternative VHC, that appropriate in vitro methods be employed to demonstrate equivalence. Methods: Particle size measurements from the Inspirachamber, Optichamber Diamond, Space chamber, Vortex and Life Brand VHCs (test devices) were compared to the AeroChamber Plus* Flow-Vu* Antistatic Background: In Phase 3 studies, subcutaneous Omalizumab (150 or 300 mg every 4 weeks for 24 weeks) was safe and effective in treating symptoms associated with CIU/CSU. OPTIMA (NCT02161562) is a novel study addressing remaining gaps in knowledge of optimal CIU/ CSU treatment. Design: Patients with CIU/CSU and symptomatic despite H1-antagonists were randomized 4:3 to Omalizumab 150 or 300 mg for 24 weeks (1st dosing period). All well-controlled patients (UAS7 ≤ 6) were then subjected to treatment withdrawal for up to 8 weeks. The patients whose symptoms came back (UAS7 ≥ 16) within this timeframe were retreated at the same dose as in the 1st dosing period. The patients who did not achieve remission during the 1st dosing period were either (1) stepped-up (150-300 mg) if symptoms were not controlled after ≥ 8 and ≤ 24 weeks; or (2) had treatment extension if symptoms were not well-controlled with 300 mg at 24 weeks. The entire study was 53 weeks. To observe a sufficient number of relapses after initial dosing with 150 or 300 mg, 314 patients were enrolled. Analysis: The primary endpoint was the proportion of patients who were clinically well controlled (UAS7 ≤ 6) after the initial dosing phase, relapsed (UAS7 ≥ 16) upon withdrawal, and who achieved a UAS7 score ≤ 6 at the end of the second dosing phase. Key secondary endpoints include: change in UAS7 score and proportion of patients UAS7 ≤ 6 in those who step-up from 150 to 300 mg; change in UAS7 score in patients who extend 300 mg treatment; time to relapse in both doses. Conclusions: This study helps identify appropriate Omalizumab treatment in CIU/CSU patients who relapse or are not well controlled after initial treatment.
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Assessing the validity and reliability of a penicillin allergy de-labeling questionnaire in pediatric patients Hannah Roberts Background: Among patients who report a penicillin allergy, more than 80% have negative testing. Patients can be erroneously labeled with a penicillin allergy due to a misclassification of the suspected reaction. This study seeks to validate a questionnaire and assessment tool that will guide physicians in identifying penicillin allergy risk groups among pediatric patients.
Methods:
The questionnaire was developed by pediatric allergists to assess history of possible penicillin allergy. Subjects are recruited from referrals to the allergy clinic for penicillin allergy assessment. Pharmacists and allergists administer the questionnaire to participants during the visit. The questionnaire answers will be assessed for inter-rater reliability. The allergist assessment and outcome from the clinic visit will be compared with follow up clinical assessment and decision forms (completed by allergy and non-allergy physicians) to assess validity. Results: We report the results of a preliminary analysis from the first 24 patients recruited between November 2016 and March 2017. 46% were male and the median age was 7 years. 79% received amoxicillin. 71% subjects reported a maculopapular rash, 42% of subjects reported urticaria. Symptoms lasted > 48 h in 55% of cases. 96% of subjects had consulted medical advice. Skin testing was not indicated in 66%. 19 subjects received amoxicillin oral challenge, and none reacted. Of 24 subjects assessed, 22 (91%) were found not to be allergic, one was deemed allergic to penicillin and one was diagnosed with severe adverse drug reaction. Conclusions: Most patients received amoxicillin and presented with prolonged maculopapular rashes or urticaria. The majority of subjects referred were deemed not allergic after an allergist assessment. Most patients are not deemed allergic based on history alone and pass drug challenges, without need for skin testing. The availability of a clinical tool to guide physicians in assessing risk level for possible penicillin allergy would decrease risk of erroneous penicillin allergy labels.
Background: Common variable immunodeficiency (CVID) is associated with numerous non-infectious manifestations, including chronic liver disease. Nodular regenerative hyperplasia (NRH) has been identified as the most common form of liver pathology in CVID patients, with these patients being at risk of the attendant complications of hepatic dysfunction. We present a case of hepatopulmonary syndrome in a CVID patient with possible NRH. Case presentation: A 52-year-old male with CVID on immunoglobulin replacement for approximately 30 years presented with progressive dyspnea out of keeping of his known mild bronchiectasis. He had previously been investigated for liver disease based on elevated liver enzymes, splenomegaly, and thrombocytopenia; however, the liver biopsy showed only non-specific sinusoidal fibrosis without evidence of cirrhosis. Pulmonary function testing was notable for a DLCO of 50% predicted and an alveolar-arterial gradient of 50 mmHg. Lung perfusion imaging was positive for a right-to-left shunt and a contrast-enhanced transthoracic echocardiogram confirmed extracardiac shunting. There was also evidence of portal hypertension with esophageal varices and portal hypertensive gastropathy. Repeat liver biopsy showed sinusoidal dilatation and fibrosis with features of NRH but was non-diagnostic. Discussion: This case illustrates the possibility of complex, multiorgan dysfunction in CVID. A diagnosis of hepatopulmonary syndrome is made by demonstrating impaired oxygenation and intrapulmonary vascular dilatations in a patient with liver disease, and it should be considered in the evaluation of dyspnea in CVID patients when more common causes have been excluded. Liver transplant, the only treatment for hepatopulmonary syndrome, should not be withheld from CVID patients on the basis of their immunodeficiency given that longterm survival in CVID transplant recipients has been documented.
Consent:
Written consent was obtained from the patient. Case study: Treatment with human immunoglobulin is indicated in various medical conditions including autoimmune diseases, infections and immunodeficiency syndromes. Serious cutaneous adverse reactions due to immunoglobulin therapy are rare and most often associated with patients with neurologic conditions who are receiving higher doses of intravenous immunoglobulin (IVIG) infusions. We report two cases of rash associated with patients receiving subcutaneous immunoglobulin (SCIG) therapy for IgG deficiency. One patient developed a painful erythematous inframammary rash soon after the initiation of SCIG therapy, persisting beyond the cessation of therapy. Trial of a different SCIG product also resulted in similar rash. The second patient developed a blistering erythematous rash on the legs after a few years of uneventful immunoglobulin therapy. The mechanism of these cutaneous reactions is not clear. There are a number of proposed theories in the literature for rash associated with immunoglobulin therapy, such as T cell mediated pathway, complement mediated immune complex deposition and IgE involvement. Although these cutaneous reactions were not life threatening, they resulted in the cessation of a beneficial therapy. Further analysis of similar cases may be helpful to understand the underlying pathophysiology of these reactions.
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Consent:
Informed verbal consent to publish is obtained from both patients with written consent to follow. Background: Ginseng has become increasingly popular in North America due to its proposed medicinal effects. Although cases of anaphylaxis have been reported in adults in response to Korean ginseng, there are no reported cases of allergy to American ginseng, nor reported cases in pediatric patients. We present a unique case of anaphylaxis to American ginseng in a 6-year-old girl. Clinical case: A 6-year-old girl with a history of multiple IgE-mediated food allergies (peanuts, tree nuts and fish), atopic dermatitis, and a remote history of asthma was presented to the emergency department with urticaria, coughing, and wheezing. Symptoms began minutes after entering a store selling powdered American ginseng. On physical examination, she had wheezing bilaterally and diffuse urticaria. She was treated with salbutamol, dexamethasone and diphenhydramine. Symptoms resolved shortly after treatment, and she was referred for allergy testing. Skin prick testing (SPT) with American ginseng was positive with a 13x12 mm wheal. Spirometry was entirely normal (FEV1 107% predicted). A basophil activation test (BAT) showed a dose-dependent increase in expression of CD63 on basophils in response to American ginseng extract, but not to Korean ginseng extract. No changes were observed in a non-atopic control, and minimal changes were observed in an atopic control. It was concluded that this patient had an anaphylactic reaction to American ginseng. She was advised to strictly avoid all ginseng products and carry an epinephrine autoinjector at all times.
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Conclusion:
We present a unique case of anaphylaxis with physician-confirmed respiratory symptoms and urticaria, with evidence of sensitization to ginseng on SPT and allergy on BAT. This is the first reported case of ginseng anaphylaxis in a pediatric patient, in addition to anaphylaxis to American ginseng. As ginseng exposure is becoming increasingly prevalent in North America, it is important to consider ginseng as a cause of allergic presentation in children.
Consent to publish:
Written informed consent to publish was obtained from the patient's guardians. Case: We present a case of a 22-year old security officer with severe CRSwNP and aspirin associated respiratory disease (AERD). His medical history included asthma with ragweed pollen sensitization, elevated serum IgE (122), and peripheral eosinophilia (500/μL). Investigations for vasculitis, aspergillus sensitization, immunodeficiency, cystic fibrosis, and primary ciliary disorders were negative. Despite multiple endoscopic sinus surgeries and maximal medical therapy (saline and 0.5 mg budesonide irrigation, and aspirin 650 mg, twice daily), his symptoms persisted. Mucocele development and invasion into the ipsilateral orbit led to orbital abscess formation and visual compromise, necessitating urgent surgical decompression. Intra-operatively, the middle and superior turbinates were noted to have complete polypoid transformation. Based on his history of refractory CRSwNP, asthma, and peripheral eosinophilia, he was started on the anti-IL5 mAb mepolizumab. After three monthly 100 mg subcutaneous infusions, he had significant improvement in nasal obstruction and purulent rhinorrhea, and complete return of olfaction. His visual acuity and extra-ocular movements returned to baseline. Endoscopy revealed no evidence of polyp recurrence or ongoing inflammation. Conclusion: Several clinical trials have evaluated the safety and efficacy of biologics in CRSwNP. The anti-IgE monoclonal antibody omalizumab and anti-IL-4 receptor antibody dupilumab demonstrated efficacy in reducing polyp size and improving nasal symptoms as long term therapy. Anti-IL-5 therapy has only been studied as single dose treatment. Our case illustrates the potential therapeutic benefit of extended anti-IL-5 therapy to induce disease remission in patients with medically and surgically refractory CRSwNP.
Consent:
Written informed consent for the publication of these details was obtained from the patient. Background: Food allergy affects approximately 2% of adults. The most common adult triggers include fruits and vegetables; delayed sensitization may develop due to shared homologous proteins with airborne allergens (i.e., pollens). Mast cells are associated with allergic diseases, including asthma, atopic dermatitis, and medication hypersensitivity. In contrast, the association of adult onset food allergy with mast cell disorder has not been well described. Case study: We present a case of a 55-year-old man with a three-year history of recurrent syncope, associated with almond and yellow pepper ingestion. He also reported sporadic flushing and pruritus without eruption. Skin testing with fresh extracts of almonds and yellow pepper was positive. Baseline serum tryptase levels were elevated, with serial values of 29, 32, and 37 (normal < 11.4) ng/mL. Investigations included normal serum immunoglobulins, protein electrophoresis, and 24-h urine 5-hydroxyindoleacetic acid, vanillylmandelic acid and metanephrines. Liver and renal function were normal, with two abdominal ultrasounds confirming normal liver and spleen size and echotexture. Bone marrow analysis indicated normal tri-lineage hematopoiesis with normal maturation, and minimal infiltration by mast cells. Given his elevated tryptase, and diagnosis of an IgEdependent disease related mast cell disorder, the patient was maintained on cetirizine, and advised to avoid almonds and yellow pepper. He was prescribed epinephrine auto-injectors. To date, there is one case report of shellfish anaphylaxis associated with mast cell activation syndrome (MCAS). In contrast, there is an established association, and parameters for management, of mast cell disorders associated with venom allergy [stinging insect parameter]. In our patient, it is unclear whether the mast cell disorder was incidentally discovered and secondary to an IgE mediated allergy, or if mast cell dysfunction unmasked sub-clinical food sensitizations. MCAS can predispose to severe anaphylaxis reactions. In adults with newly discovered food allergy, clinicians should have a high suspicion for newly acquired or indolent mast cell disorders, particularly if there is a history of severe cardiovascular compromise.
The patient provided written informed consent for publications of the details in this case report. 
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Conclusion:
There is no current treatment for HES patients not caused by M-HES or L-HES who have failed first and second line agents. Past trials with high dose mepolizumab 750 mg IV for idiopathic HES showed good response. We report use of Mepolizumab 100 mg subcutaneous q 4 weeks for 5 doses, with complete amelioration of symptoms.
Consent:
Written informed consent was obtained from the patient for publication of this abstract. A copy of the written consent is available for review by the editor of this journal. 
